e the care of MS patients. Ocrevus has a new and shorter infusion solution(2 hours)that has been approved in the United States and the European Union.
PRINCIPAL DISPLAY PANEL-300MG/10ML VIAL CARTON
NDC 50242-150-01
Ocrevus(ocrelizumab)Injection
300mg/10mL(30mg/mL)
For Intravenous Infusion.
Must Be Diluted.
Single-Dose Vial.
Discard Unused Portion.
Attention Pharmacist: Dispense theaccompanying Medication Guide toeach patient.
Rx only
1 vial
Genentech |
